Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease

Huan Liu, Jin He, Su Pin Koh, Yuping Zhong, Zhiqiang Liu, Zhiqiang Wang, Yujin Zhang, Zongwei Li, Bjorn T. Tam, Pei Lin, Min Xiao, Ken H. Young, Behrang Amini, Michael W. Starbuck, Hans C. Lee, Nora M. Navone, Richard E. Davis, Qiang Tong, P. Leif Bergsagel, Jian HouQing Yi, Robert Z. Orlowski, Robert F. Gagel, Jing Yang*

*Corresponding author for this work

    Research output: Contribution to journalJournal articlepeer-review

    77 Citations (Scopus)

    Abstract

    Osteolytic lesions in multiple myeloma are caused by osteoclast-mediated bone resorption and reduced bone formation. A unique feature of myeloma is a failure of bone healing after successful treatment. We observed adipocytes on trabecular bone near the resorbed area in successfully treated patients. Normal marrow adipocytes, when cocultured with myeloma cells, were reprogrammed and produced adipokines that activate osteoclastogenesis and suppress osteoblastogenesis. These adipocytes have reduced expression of peroxisome proliferator–activated receptor γ (PPARγ) mediated by recruitment of polycomb repressive complex 2 (PRC2), which modifies PPARγ promoter methylation at trimethyl lysine-27 histone H3. We confirmed the importance of methylation in the PPARγ promoter by demonstrating that adipocyte-specific knockout of EZH2, a member of the PRC2, prevents adipocyte reprogramming and reverses bone changes in a mouse model. We validated the strong correlation between the frequency of bone lesions and the expression of EZH2 in marrow adipocytes from patients in remission. These results define a role for adipocytes in genesis of myeloma-associated bone disease and that reversal of adipocyte reprogramming has therapeutic implications.
    Original languageEnglish
    JournalScience Translational Medicine
    Volume11
    Issue number494
    DOIs
    Publication statusPublished - 29 May 2019

    Fingerprint

    Dive into the research topics of 'Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease'. Together they form a unique fingerprint.

    Cite this